Drug profile · INN
inebilizumab-cdon
UPLIZNA
inebilizumab-cdon (UPLIZNA) is a b-lymphocyte antigen cd19 binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — inebilizumab-cdon
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
inebilizumab-cdon (UPLIZNA) is a b-lymphocyte antigen cd19 binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
B-lymphocyte antigen CD19 binding agent
Primary target: B-lymphocyte antigen CD19
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is inebilizumab-cdon?
inebilizumab-cdon (UPLIZNA) is a b-lymphocyte antigen cd19 binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for inebilizumab-cdon?
UPLIZNA is a marketed brand name for inebilizumab-cdon. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of inebilizumab-cdon?
inebilizumab-cdon has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.